Key statistics
On Friday, ACADIA Pharmaceuticals Inc (ACAD*:MEX) closed at 447.05, 0.00% below its 52-week high of 447.05, set on Nov 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 447.05 |
|---|---|
| High | 447.05 |
| Low | 447.05 |
| Bid | -- |
| Offer | -- |
| Previous close | 386.83 |
| Average volume | -- |
|---|---|
| Shares outstanding | 169.18m |
| Free float | 168.26m |
| P/E (TTM) | 14.19 |
| Market cap | 3.73bn USD |
| EPS (TTM) | 1.55 USD |
Data delayed at least 20 minutes, as of Nov 28 2025 11:30 GMT.
More ▼
Press releases
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
- Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
More ▼
